“Neurobiologic Advances from the Brain Disease Model of Addiction”. N. Engl. J. Med.374 (4): 363–371. (January 2016). doi:10.1056/NEJMra1511480. PMID26816013.
Quaglio G, Schifano F, Lugoboni F (September 2008). “Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse”. Addiction103 (9): 1572–4. doi:10.1111/j.1360-0443.2008.02266.x. PMID18636997.
Wolfgang Löscher and Dieter Schmidt (August 2006). “Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs”. Epilepsia47 (8): 1253–1284. doi:10.1111/j.1528-1167.2006.00607.x. PMID16922870.
“Neurobiologic Advances from the Brain Disease Model of Addiction”. N. Engl. J. Med.374 (4): 363–371. (January 2016). doi:10.1056/NEJMra1511480. PMID26816013.
Landry MJ, Smith DE, McDuff DR, Baughman OL (1992). “Benzodiazepine dependence and withdrawal: identification and medical management”. J Am Board Fam Pract5 (2): 167?75. PMID1575069.
Quaglio G, Schifano F, Lugoboni F (September 2008). “Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse”. Addiction103 (9): 1572–4. doi:10.1111/j.1360-0443.2008.02266.x. PMID18636997.
Danke F (1975). “[Methylphenidate addiction--Reversal of effect on withdrawal]” (German). Psychiatr Clin (Basel)8 (4): 201–11. PMID1208893.
Cohen D, Leo J, Stanton T, et al. (2002). “A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study”. Ethical Hum Sci Serv4 (3): 189–209. PMID15278983.
Chichmanian RM, Gustovic P, Spreux A, Baldin B (1993). “[Risk related to withdrawal from non-psychotropic drugs]” (French). Therapie48 (5): 415–9. PMID8146817.
Wolfgang Löscher and Dieter Schmidt (August 2006). “Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs”. Epilepsia47 (8): 1253–1284. doi:10.1111/j.1528-1167.2006.00607.x. PMID16922870.